By Dean Seal
Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism.
The stock fell 68% to a low of $4.17 in early trading. The stock just hit the market last fall.
The clinical-stage biotech company said Tuesday that it would stop the trial based on two unanticipated and severe events that didn't cause liver injury or other serious adverse effects, but prompted the discontinuation of dosing for both study participants.
The company said it would initiate non-clinical studies to investigate what was observed during phase 1.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:26 ET (15:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。